TG Therapeutics (TGTX) Misses Q3 EPS by 19c

TG Therapeutics (NASDAQ: TGTX) reported Q3 EPS of ($0.51), $0.19 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $38.1 million versus the consensus estimate of $30 thousand.

For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.

You May Also Be Interested In

• BofA lists top 5 themes driving next $1tn in incremental semi sales
• Tetra4 signs first helium supply deal for South Africa gas project
• Morgan Stanley Starts Adani Enterprises Ltd. (ADE:IN) at Overweight